Literature DB >> 26387561

Pseudohypoparathyroidism - epidemiology, mortality and risk of complications.

Line Underbjerg1, Tanja Sikjaer1, Leif Mosekilde1, Lars Rejnmark1.   

Abstract

OBJECTIVE: Pseudohypoparathyroidism (PHP) is caused by a mutation within the GNAS gene or upstream of the GNAS complex locus. It is characterized by target organ resistance to PTH, resulting in hypocalcaemia and hyperphosphataemia. Studies in patients with PHP are limited. We sought to identify all patients in Denmark with PHP and access their mortality data and risk of complications.
DESIGN: Patients were identified through the Danish National Patient Registry and a prescription database, with subsequent validation by investigation of patient charts.
METHODS: For each case, three age- (±2 years) and gender-matched controls were randomly selected from the general background population. We identified a total of 60 cases, equal to a prevalence of 1·1/100 000 inhabitants. The average age at diagnosis was 13 years (range 1-62 years), and 42 were women. Only 14 patients had an identified mutation in the GNAS1 gene.
RESULTS: Compared with controls, patients with PHP had an increased risk of neuropsychiatric disorders (P < 0·01), infections (P < 0·01), seizures (P < 0·01) and cataract (P < 0·01), whereas their risk of renal, cardiovascular, malignant disorders and fractures was compatible with the general background population. The same tendencies were found in a subgroup analysis in cases with genetically verified PHP.
CONCLUSION: Patients with PHP have an increased risk of neuropsychiatric disorders, infections, cataract and seizures, whereas mortality among PHP patients is compatible with that in the background population.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26387561     DOI: 10.1111/cen.12948

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  17 in total

Review 1.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

Review 2.  Nonclassic features of pseudohypoparathyroidism type 1A.

Authors:  Ashley H Shoemaker; Harald Jüppner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

3.  Early-Onset Obesity: Unrecognized First Evidence for GNAS Mutations and Methylation Changes.

Authors:  Annette Grüters-Kieslich; Monica Reyes; Amita Sharma; Cem Demirci; Terry J DeClue; Erwin Lankes; Dov Tiosano; Dirk Schnabel; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

4.  Identification of a Novel Mutation in a Family with Pseudohypoparathyroidism Type 1a.

Authors:  Adelaide Moutinho; Rosa Carvalho; Rita Ferreira Reis; Sandra Tavares
Journal:  Case Rep Endocrinol       Date:  2018-01-22

5.  Identification of a novel GNAS mutation in a case of pseudohypoparathyroidism type 1A with normocalcemia.

Authors:  Xiao-Dan Long; Jing Xiong; Zhao-Hui Mo; Chang-Sheng Dong; Ping Jin
Journal:  BMC Med Genet       Date:  2018-07-30       Impact factor: 2.103

Review 6.  Management of pseudohypoparathyroidism.

Authors:  Emily L Germain-Lee
Journal:  Curr Opin Pediatr       Date:  2019-08       Impact factor: 2.856

Review 7.  Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Aurora Garcia Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen A T Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Manasori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebeca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Horm Res Paediatr       Date:  2020-08-05       Impact factor: 2.852

8.  Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway.

Authors:  Marianne C Astor; Kristian Løvås; Aleksandra Debowska; Erik F Eriksen; Johan A Evang; Christian Fossum; Kristian J Fougner; Synnøve E Holte; Kari Lima; Ragnar B Moe; Anne Grethe Myhre; E Helen Kemp; Bjørn G Nedrebø; Johan Svartberg; Eystein S Husebye
Journal:  J Clin Endocrinol Metab       Date:  2016-05-17       Impact factor: 5.958

9.  Manifestations of left ventricular dysfunction and arrhythmia in patients with chronic hypoparathyroidism and pseudohypoparathyroidism: a preliminary study.

Authors:  Yabing Wang; Kun He; Ou Wang; Xue Lin; Sixing Chen; Yan Jiang; Mei Li; Weibo Xia; Xiaoping Xing
Journal:  BMC Endocr Disord       Date:  2020-05-11       Impact factor: 2.763

Review 10.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.